{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T21:39:44Z","timestamp":1774993184019,"version":"3.50.1"},"reference-count":0,"publisher":"Bentham Science Publishers Ltd.","issue":"10","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CNSNDDT"],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:sec>\n<jats:title>:<\/jats:title>\n<jats:p>Alzheimer\u2019s Disease (AD) is one of the most common neurodegenerative diseases,\nwhich affects millions of people worldwide. Accumulation of amyloid-\u03b2 plaques and hyperphosphorylated\nneurofibrillary tangles are the key mechanisms involved in the etiopathogenesis of AD,\ncharacterized by memory loss and behavioural changes. Effective therapies targeting AD pathogenesis\nare limited, making it the largest unmet clinical need. Unfortunately, the available drugs provide\nsymptomatic relief and primary care, with no substantial impact on the disease pathology.\nHowever, in recent years researchers are working hard on several potential therapeutic targets to\ncombat disease pathogenesis, and few drugs have also reached clinical trials. In addition, drugs are\nbeing repurposed both in the preclinical and clinical studies for the treatment of AD. For instance,\nmontelukast is the most commonly used leukotriene receptor antagonist for treating asthma and seasonal\nallergy. Its leukotriene antagonistic action can also be beneficial for the reduction of detrimental\neffects of leukotriene against neuro-inflammation, a hallmark feature of AD. The available\nmarketed formulations of montelukast present challenges such as poor bioavailability and reduced\nuptake, reflecting the lack of effectiveness of its desired action in the CNS. While on the other side,\ntargeted drug delivery is a satisfactory approach to surpass the challenges associated with the therapeutic\nagents. This review will discuss the enhancement of montelukast treatment efficacy and its\naccess to CNS by using new approaches like nano-formulation, nasal gel, solid lipid formulation,\nnano-structure lipid carrier (NSLC), highlighting lessons learned to target AD pathologies and hurdles\nthat persist.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1871527320666210902163756","type":"journal-article","created":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T13:46:44Z","timestamp":1630676804000},"page":"913-925","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Targeted Delivery of Montelukast for the Treatment of Alzheimer\u2019s\nDisease"],"prefix":"10.2174","volume":"21","author":[{"given":"Ashok K.","family":"Datusalia","sequence":"first","affiliation":[{"name":"Department of Pharmacology and Toxicology - National Institute of Pharmaceutical Education and Research\n(NIPER) Raebareli, India"},{"name":"Department of Regulatory Toxicology - National Institute of Pharmaceutical Education\nand Research (NIPER), Raebareli, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gurpreet","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology - National Institute of Pharmaceutical Education and Research\n(NIPER) Raebareli, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikita","family":"Yadav","sequence":"additional","affiliation":[{"name":"Department of Regulatory Toxicology - National Institute of Pharmaceutical Education\nand Research (NIPER), Raebareli, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sachin","family":"Gaun","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology - National Institute of Pharmaceutical Education and Research\n(NIPER) Raebareli, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moumita","family":"Manik","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology - National Institute of Pharmaceutical Education and Research\n(NIPER) Raebareli, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rakesh K.","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology - National Institute of Pharmaceutical Education and Research\n(NIPER) Raebareli, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","container-title":["CNS &amp; Neurological Disorders - Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1871527320666210902163756","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/196114\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1871527320666210902163756","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,11]],"date-time":"2022-09-11T02:05:17Z","timestamp":1662861917000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/196114\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":0,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1871527320666210902163756","relation":{},"ISSN":["1871-5273"],"issn-type":[{"value":"1871-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-12-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-21","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}